Gossamer Bio Inc (GOSS)
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company listed on NASDAQ under the ticker GOSS. The company is focused on developing and commercializing seralutinib for pulmonary hypertension, including pulmonary arterial hypertension, in the United States. Its pipeline also includes GB002, an inhaled small-molecule inhibitor targeting PDGFR, colony-stimulating factor 1 receptor, and c-KIT, which is in Phase 3 clinical testing for PAH. Gossamer Bio has license agreements with Pulmokine, Inc. covering GB002 and related backup compounds. Founded in 2015 and formerly known as FSG, Bio, Inc., the company adopted its current name in 2017 and is headquartered in San Diego, California.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-GOSS
|
$15.90
|
36.0% Upside
|
Undervalued
|
$122.48
|
947.7% Upside
|
Bargain
|
Weak
|
0.0%
|
November 5, 2026
|
1.3x
|
71.433 M
|
54.475 M
|
36.8%
|
62.7%
|
-33.6
|
129.9%
|
